
‘We shouldn't use Mounjaro as a way to get skinny': Dr Alexandra Sowa
An obesity and internal medicine specialist based in New York, Dr Alexandra Sowa has been researching and practising obesity medicine for about a decade now. For her — and her practice at her company So Well — Ozempic is not much of a revolution. But her new book belies that familiarity. Titled The Ozempic Revolution, it's the first comprehensive user guide to GLP-1s—from the science and pop culture resonances of weight loss drugs and detailed guides to optimising benefits.
Also read: Mounjaro in India: The speed bumps impacting access to weight loss drugs
The book released in India around the same time as Mounjaro. In India, the GLP-1 drug is already in prescriptions. Dr Muffazal Lakdawala, director, department of general surgery and minimal access surgery, Sir HN Reliance Foundation Hospital, Mumbai, says, 'It's my belief that given its efficacy in controlling diabetes and excessive weight, the affordable price points in India ( ₹3500 for a 2.5 ml vial), Mounjaro will do very well in India — as it should. Both diabetes and obesity are huge problems in India, so interest and curiosity about this drug is already very very high."
In an interview over Zoom, Sowa spoke to Lounge about her experiences with the drug, what gives Mounjaro an extra edge over other GLP-1s, and how these weight loss medications could be beneficial to women. Edited excerpts:
Based on your experience treating people with GLP-1s, what is your honest estimate about the effect this category of drugs will have on humankind?
I was one of the first and earliest adopters of GLP-1 medications in the US. In my years as a student at Johns Hopkins and New York University, I realised that much of medical education was focused on end-stage disease management. So you would get sick and then we would manage you — despite the fact that most doctors know so many of chronic diseases are due to metabolic dysfunction and excess weight.
When I found this specialty of obesity medicine that was really evolving and coming out into the world about 15-20 years ago, there was no looking back. I developed my own protocol for my patients at So Well. And our method worked so well that I really felt like I had to put it into a book to help all of the people who are now getting expanded access to these medications. The thing you need to know is, a prescription does not just mean success on these medications. You need to know how to thrive: How to eat, think, live and most importantly, how to change your relationship with food.
Recently, a mildly overweight friend casually said she was considering Mounjaro. Who is the ideal candidate for this kind of drug?
Well, it depends — on government directives and other factors. I'm not entirely sure what regulations India has set. In the US, someone with a Body Mass Index (BMI) greater than 27 with one or more health issues related to their raised BMI is a good candidate. Technically, Mounjaro is approved also for type 2 diabetes. One thing we should talk about though is that we shouldn't be using this just as a way to get skinny. It's really important to look at all of the metabolic health parameters, family history, and doing a really good deep dive. If you treat this like a quick fix, it's going to be like any other crash diet.
Also read: Vasudha Rai on why it's time to reconnect with the healing power of plants
As I understand after reading the book, just taking the medication and forgetting about everything else is not going to work. Can you elaborate on the three foundations you talk about in the book for anybody on Mounjaro or Ozempic?
Yes, they are the habit foundation, the food foundation and the mental foundation.
We start with the habit foundation — learning how to track our food, not for calories but really for understanding why we're eating. Are we hungry? The food foundation is about meal planning. How am I going to get my protein in? Am I going to do eggs today? Am I going to do beans? Am I going to do meat? Protein is the most important macronutrient that you (ought to) get in every meal because your body doesn't have a lot of capacity to eat when we start these medications. I take people through what a robust diet looks like. And then finally the thing that nobody talks about but I think is potentially the most important: the mental foundation. How are you thinking about this journey? How will you respond to criticism? How do you respond to that headline that tries to give you fear or inspiration? This journey is not about skinny, it is about health.
There's been a lot of talk about the side effects too. What does it really feel like to be on this drug?
The good news about side effects for India is that Mounjaro has less side effects than earlier versions of the drug. But generally the side effects are really a by-product of how the medication works. The decreased stomach emptying can lead to some gastrointestinal upset, especially if you don't pay attention to the volume of food you're taking in. There can be some nausea, and fatigue, which gets better over time.
The effect of these drugs on muscles is well documented. Protein plus strength training seems to be the magic formula. Is that correct?
The final foundation in the book is exercise. Historically, exercise has been sold to us as something that if we did it would lead to weight loss. And so you should join the gym, do this class, sweat until you die. Exercise is not actually very good for weight loss. It's very good for cardiovascular health. It is very important for weight maintenance.
Also read: Body Roundness Index: Is this measure a better indicator of your health?
Once people start losing weight, what I want them to do is move – move in a way that just feels joyful to them. Is that walking? Is that going to a cycling class? Is it riding your bike? Just move. But what's important is we work on keeping our muscle strength up. And we do that through lifting weights. Heavy weights are great, but they're not appropriate for everyone. Luckily, on Mounjaro, you tend to lose a little more fat than muscle. If you add strength training into that mix, you're better off.
Do women and men have different responses to this class of drugs? Especially menopausal women for whom weight gain tends to be significant…
Yes. For the first time ever, women actually have superior weight loss on this drug than men. It is pretty revolutionary for the woman in menopause, who traditionally was kind of told, 'See, you will just have to deal with the insulin resistance that comes and the disease that comes and the weight gain that will come". It can be a great tool for menopausal weight gain.
In India, the Ozempic story has been one of hype. It's about celebrities suddenly looking gaunt with their 'Ozempic face". What are your thoughts on this hype?
On one hand, of course it's dangerous because you are looking at this medication for thinness, beauty and aspiration. On the other hand, with widespread coverage, what I have found is that the trickle-down effect in the US on diseases has been remarkable. 'Oprah's on it, so I'll be on it." I've been prescribing this class of drugs for a long time. Up until about 24 months ago, I would have to really have a very long conversation with patients and almost talk them into or offer these drugs. Now people are just calling the office non-stop saying, 'Oh, I qualify for this medication".
Once you are on, say, Mounjaro, is it going to be a lifetime thing?
If people stop this drug, 95% of them will regain the majority of their weight by five years. So the answer is yes. For most people, once you start this drug for weight management, you will need to continue it for a very long time, potentially indefinitely.
So many of us have experienced the guilt and the shame of being overweight. And the judgements are always based on a perception that being overweight is about dysfunctional will power and behaviour, not biology. Your book shatters that myth.
Let's quickly talk about the science of weight gain. And you are correct, it's not just willpower. Because once weight starts to come on, for the vast majority of people, it becomes very hard to take off. Why? Because the connection between your hormones, your brain and your gut become disregulated.
So yes, it's important what we eat, and it's important how we move, but there are bigger factors beyond us: our environment, pollutants, microplastics, the quality of food, our genes. In overweight people, hormones don't keep a checks-and-balance system the way that they're supposed to. What happens when hormones are in disregulation is that our hunger hormones surge, our fullness hormones tank, insulin and leptin resistance change the way that our body looks and craves food, and our brain changes too. GLP-1 agonist medications like Ozempic and Mounjaro work on this dysfunctional pathway, and they fix the relationship between the brain and the gut. It specifically works through what I call the three superpowers: It works on our brain, on our gut, and at the level of our pancreas and blood sugar.
Sanjukta Sharma is a Mumbai-based writer and journalist and runs the health and wellness IP The Slow Fix @the_slow_fix (on Instagram) and @TheSlowFix on YouTube.
Also read: What body positivity means in the age of Ozempic
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


India Today
5 hours ago
- India Today
European drugs regulator flags rare eye risk with Ozempic
The European Medicines Agency's safety committee has concluded that the use of Novo Nordisk's popular weight-loss drug Wegovy and its treatments for type 2 diabetes may cause rare occurrences of a potentially dangerous eye non-arteritic anterior ischemic optic neuropathy (NAION), the condition may affect up to 1 in 10,000 people taking semaglutide, the active ingredient in Wegovy and Novo's diabetes drugs Ozempic and Rybelsus, the regulator said on EMA, which started its review in December, said the use of the drugs is linked to about twofold increase in the risk of developing the condition compared to people not taking the medicine. NAION develops from insufficient blood flow to the optic nerve and causes sudden painless vision loss in one eye. It is the second most common cause of blindness due to optic nerve damage, after have linked semaglutide to NAION in the past. But this is the first time a regulator has made the belongs to a class of drugs known as GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness.A large study of nearly 350,000 diabetics published earlier this year had showed that the risk of developing NAION more than doubled after long-term use of semaglutide, compared to patients taking medicines from other EMA said it has reviewed all available data on NAION with semaglutide, including data from non-clinical studies, clinical trials and has recommended the drugmaker to update prescribing information for medicines containing semaglutide to include NAION as a side effect with a frequency of "very rare".The US Food and Drug Administration did not immediately respond to a Reuters request for Watch
&w=3840&q=100)

Business Standard
9 hours ago
- Business Standard
NB.1.8.1 Covid-19 variant makes up 10% cases globally: Should you worry?
Just when many believed Covid-19 was in the rear-view mirror, a new variant has quietly gained ground. NB.1.8.1, first detected in China in January 2025, now accounts for one in ten Covid-19 cases globally—up from just one in forty a month ago. It has spread across twenty-two countries so far. What is NB.1.8.1 variant? According to the World Health Organization, NB.1.8.1 is among several fast-evolving Omicron-lineage variants. From January to May 2025, global dominance shifted from XEC to LP.8.1, with NB.1.8.1 now surging rapidly. The WHO has classified NB.1.8.1 as a Variant Under Monitoring due to its rise in prevalence and potential public health implications. Officials stress that while vigilance is crucial, there is no cause for alarm. Vaccination remains the best protection against severe illness and death. How NB.1.8.1 behaves and how severe it really is NB.1.8.1 is a sublineage of the Omicron JN.1 family. It carries similar characteristics—high transmissibility, but mostly mild to moderate illness. It also includes new mutations on the spike protein, which may enhance its ability to spread and evade immunity. So far, there is no evidence to suggest NB.1.8.1 causes more severe disease, hospitalisations or death compared to previous variants. NB.1.8.1 symptoms: What to watch for Common symptoms include: Dry, persistent cough Runny or blocked nose Fatigue and general body aches Sore throat Fever or chills Headache or hoarseness in some cases Many report being able to go about daily activities but feel unusually tired and sluggish. Are vaccines still effective against NB.1.8.1? Updated vaccines, including the latest Omicron-targeted boosters, are designed to protect against the JN.1 family. While they may not prevent all infections, they continue to reduce the risk of hospitalisation and severe outcomes. Expert guidance includes: If you are over sixty, have chronic health conditions or are immunocompromised, get a booster if it has been more than six months since your last dose If you are healthy and under sixty, no new dose is required at present Use masks in public transport and crowded indoor spaces How to manage NB.1.8.1 symptoms at home In most cases, NB.1.8.1 does not require hospitalisation. Here is what helps: Rest and stay well hydrated Use paracetamol or other over-the-counter medications for fever or aches Recovery generally takes five to seven days If you are elderly or immunocompromised, speak to your doctor early. Antiviral medication is most effective within five days of the onset of symptoms. Warning signs: When to seek emergency help Seek urgent medical care if you experience any of the following: Difficulty breathing Chest pain or tightness Confusion or trouble staying awake Severe dizziness or fainting Do not panic, but stay informed Experts believe NB.1.8.1 will follow a familiar seasonal pattern seen with earlier variants—periodic surges during winter and summer months. Most infections remain mild. Vaccines continue to work. Keep an eye on symptoms, isolate if unwell, and consult your doctor when in doubt.


New Indian Express
11 hours ago
- New Indian Express
Covid infections growing milder, occasional surges expected but don't worry: experts
The death toll is 55 in the current surge which started January this year, primarily among individuals with pre-existing illnesses, according to the Union Health ministry. "People with pre-existing illnesses and those older than 65 should follow standard precautions, as they would against any other respiratory infection -- not just for COVID-19," explained Lahariya, a consultant physician and former staff member of WHO. Kerala is the most affected with over 1,600 cases, followed by Gujarat, West Bengal, Delhi and Maharashtra, ministry data shows. The case surge in India is part of a wider wave impacting parts of Southeast Asia, including Singapore, Malaysia, Thailand and Hong Kong, which have been seeing a rise in infections over the past months. Wastewater surveillance by the Council of Scientific and Industrial Research-National Chemical Laboratory (NCL) has detected presence of SARS-CoV-2 -- which causes COVID-19 -- in samples from 10 sewage treatment plants in Pune, the Times of India reported. Patterns are similar to those seen in the weeks preceding earlier surges, NCL scientists were quoted as saying. Genome sequencing of samples from India's west and south have shown links to the subvariants of Omicron -- LF.7, XFG, JN.1 and NB.1.8.1. The cases are not severe and there is no need to worry, Director General of Indian Council of Medical Research (ICMR) Rajiv Behl said earlier this week. LF.7 and been classified as 'variants under monitoring' (VUM) by the WHO to alert public health authorities that a variant of SARS-CoV-2 requires prioritised attention and monitoring. JN.1 has been circulating in India since November 2023. The current situation, Behl stressed, is being monitored. Immunologist Satyajit Rath explained that the subvariants driving up case numbers indicate that they are probably better at binding themselves to human cells, despite pre-existing antibodies created in response to a prior infection or vaccination -- or 'infectivity'. "However, the important issue here is not their infectivity, but their tendency to cause severe disease, or 'virulence'," Rath, former scientist at New Delhi's National Institute of Immunology, told PTI. "Since selection pressure among the virus strains depends on infectivity and transmissibility -- and not on virulence -- there is no reason to expect a steady increase in the virulence of the emerging virus strains, which, in fact, has not at all been seen either," he added. Moreover, given that the COVID-19-causing virus is now endemic and constantly 'mutating' or evolving, ups and downs in infections in the population are expected, the health experts said. "People need not worry themselves until they are informed of a new 'variant of concern'. VUM is not relevant to the public, but only to public health authorities," Agarwal said. Lahariya advised the public to gather information from reliable sources and not to forward unverified messages, while Rath suggested that citizens keep a watch for the virulence of newly emerging strains. The experts also stressed on the role of authorities. "National and state governments in India should keep a watch on cases, monitor the trends in new cases and share data widely. The linkage between infections and clinical outcomes should be explored to understand the clinical features of the variants in circulation," Lahariya said. Rath drew attention to systemic issues that remain regarding preparedness of public health systems and availability of healthcare facilities across sections of the society should a virulent variant emerge. "The catch is, how efficiently, systematically and rigorously are our public health systems tracking virus strains, their infectivity and their virulence, not only for SARS-CoV-2 but for any other infection?" he asked. "Are we making next generation Covid vaccines at all? Are we making them available widely and affordably? Are we even carefully tracking evidence to see how well or poorly the current vaccine-induced immunity functions against emerging strains?" he added. The poor and vulnerable would need special protection "but are masks being made widely and freely available? And if not, we are throwing poor communities onto their own resources even for taking such simple precautions, and that is a systemic problem," Rath said.